Biomarker Validation
Technological, Clinical and Commercial Aspects
1. Edition April 2015
XVI, 248 Pages, Hardcover
Handbook/Reference Book
ISBN:
978-3-527-33719-4
Wiley-VCH, Weinheim
Short Description
Built on a decade of experience with novel molecular diagnostics, this practice-oriented guide shows how to cope with validation issues during all stages of biomarker development, from the first clinical studies to the eventual commercialization of a new diagnostic test.
Buy now
Price: 135,00 €
Price incl. VAT, excl. Shipping
Euro prices for Wiley-VCH and Ernst & Sohn titles are only valid for Germany. In EU countries, local VAT applies. Postage will be charged.
- Out of print -
Further versions
History of Biomarkers
Biomarkers from the Discovery Phase to the Final Assay
Sample Types
Biomarkers - Past and Future
Quantitative Proteomics Techniques in Biomarker Discovery
Biomarker qualification: a company point of view
Biomarker discovery and medical diagnostic imaging
Breath: an often overlooked medium in biomarker discovery
HTA in personalized medicine technologies
Bone Remodeling Biomarkers: New Actors on the Old Cardiovascular Stage
Identification and Validation of Breast Cancer Biomarkers
Evaluation of proteomic data: from profiling to network analysis by way of biomarker discovery
Biomarkers: From discovery to commercialization
Clinical validation chapter for biomarker validation book
Genomics and Proteomics for Biomarker Validation
Biomarkers from the Discovery Phase to the Final Assay
Sample Types
Biomarkers - Past and Future
Quantitative Proteomics Techniques in Biomarker Discovery
Biomarker qualification: a company point of view
Biomarker discovery and medical diagnostic imaging
Breath: an often overlooked medium in biomarker discovery
HTA in personalized medicine technologies
Bone Remodeling Biomarkers: New Actors on the Old Cardiovascular Stage
Identification and Validation of Breast Cancer Biomarkers
Evaluation of proteomic data: from profiling to network analysis by way of biomarker discovery
Biomarkers: From discovery to commercialization
Clinical validation chapter for biomarker validation book
Genomics and Proteomics for Biomarker Validation
Harald Seitz studied Biochemistry at the Free University of Berlin, accomplished his PhD working at the MPI for Molecular Genetics in 2000 and finished his habilitation at the University of Kassel in 2012. After working for nearly 10 years at the MPI for Molecular Genetics he moved to the Fraunhofer Institute for Biomedical Engineering in 2011. The focus of his work is on high throughput techniques especially all kinds of protein and peptide microarrays and in vitro diagnostics.
Sarah Schumacher studied Biology at the Free University of Berlin and completed her M.Sc. at the Humboldt University of Berlin. Before she started her PhD in 2013, she worked at the MPI for Molecular Genetics in Berlin and moved to the Fraunhofer IBMT in Potsdam-Golm in 2011. Her research interest is on biomarker and antibody validation.
Sarah Schumacher studied Biology at the Free University of Berlin and completed her M.Sc. at the Humboldt University of Berlin. Before she started her PhD in 2013, she worked at the MPI for Molecular Genetics in Berlin and moved to the Fraunhofer IBMT in Potsdam-Golm in 2011. Her research interest is on biomarker and antibody validation.
